Technology
Health
Biotechnology

Retrophin

$24.23
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Pre-Market
$0.00 (0.00%) Pre-Market

Why Robinhood?

You can buy or sell Retrophin and other stocks, options, ETFs, and crypto commission-free!

About

Retrophin, Inc. Common Stock, also called Retrophin, is a biopharmaceutical company. Read More It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Employees
214
Headquarters
San Diego, California
Founded
2008
Market Cap
1.00B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
346.58K
High Today
$24.69
Low Today
$24.02
Open Price
$24.02
Volume
273.17K
52 Week High
$33.00
52 Week Low
$19.77

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
US
North America

News

Yahoo FinanceMar 14

Retrophin (RTRX) Reports Q4 Loss, Misses Revenue Estimates

Retrophin (RTRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to earnings of $0.07 per share a year ago.

11
Markets InsiderMar 5

Retrophin to Present at Upcoming Investor Conferences

SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the following upcoming investor conferences in March: Cowen & Company 39th Annual Health Care Conference Date: Tuesday, March 12, 2019 Time: 8:00 a.m. ET Location: Boston, MA Barclays Global Healthcare Conference Date: Thursday, March 14, 2019 Time: 1:35 p.m. ET Location: Miami, FL Live webcasts will be available at https://ir.retrophin.com/e...

17
MarketBeatFeb 28

Stock Price, News, & Analysis for Retrophin

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal di...

3

Earnings

-$0.68
-$0.43
-$0.18
$0.07
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 1, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.